Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus

Inclusion Criteria: * Chronic liver disease consistent with chronic hepatitis C infection, genotype 1, for at least 6 months * For Part A only: patients who have had a full course of interferon and ribavirin as defined by the NIH Consensus Statement for the Management of Hepatitis C: 2002 (Management of hepatitis C: 2002, 2002) and have a detectable viral titer at Screening. * For Part B only: patients who are HCV treatment-naïve with known contraindications (i.e., history of depression) to interferon and ribavirin combination therapy; patients who have started on interferon and ribavirin but stopped therapy early due to intolerance; patients who have not received interferon and ribavirin and have refused therapy * Plasma HCV RNA viral titer of ≥ 2 logs above the assay cutoff measured at Screening. * Females must be of non-child bearing potential \[i.e., 1 year post menopausal or documented as being surgically sterile\]. * Men must agree to use an acceptable form of birth control through the study and for 28 days after final dose of ANZ-521. * Liver biopsy within the last 3 years with an Ishak Score \<3 of FibroSURE test score \<0.59. * Compensated liver disease (Child-Pugh class A) with the adequate organ function as defined by study-specific laboratory tests. * Signed Informed Consent and willing and able to comply with all study procedures. Exclusion Criteria: * Patients who are null responders to interferon-based therapy as defined by a less than 1-log decrease in viral titer from baseline during treatment. * Treatment with anti-HCV therapy within one month prior to study. * History of infection with Listeria. * History of having received an experimental HCV vaccine (therapeutic or preventive). * Known allergy to both penicillin and sulfa drugs, or component of the study drug product (e.g., glycerol). * Current or prior history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical condition. * Artificial (prosthetic) joint or other artificial implant or devices that cannot be easily removed. * History of malignancy of any type, other than surgically excised non-melanomatous skin cancers or in situ cervical cancer within 5 years. * Taking certain medications such as more than 2 g of acetaminophen per day, systemic antibiotics within 14 days of study entry, another investigational product within 28 days of study entry. * Recent hospitalization or planned surgery requiring general anesthesia or sedation. * Drug screen positive for cocaine. * Positive for HIV or Hepatitis B antibodies. * Blood donation of more than 450 mL within 8 weeks of study entry. * Other condition that might affect the subject's ability to give informed consent or comply with study requirements.